Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

Autor: De Vincentis, A, D'Amato, D, Cristoferi, L, Gerussi, A, Malinverno, F, Lleo, A, Colapietro, F, Marra, F, Galli, A, Fiorini, C, Coco, B, Brunetto, M, Niro, Ga, Cotugno, R, Saitta, C, Cozzolongo, R, Losito, F, Giannini, Eg, Labanca, S, Marzioni, M, Marconi, G, Morgando, A, Pellicano, R, Vanni, E, Cazzagon, N, Floreani, A, Chessa, L, Morelli, O, Muratori, L, Pellicelli, A, Pompili, M, Ponziani, F, Tortora, A, Rosina, F, Russello, M, Cannavo, M, Simone, L, Storato, S, Vigano, M, Abenavoli, L, D'Anto, M, De Gasperi, E, Distefano, M, Scifo, G, Zolfino, T, Calvaruso, V, Cuccorese, G, Palitti, Vp, Sacco, R, Bertino, G, Frazzetto, E, Alvaro, D, Mulinacci, G, Palermo, A, Scaravaglio, M, Terracciani, F, Galati, G, Ronca, V, Zuin, M, Claar, E, Izzi, A, Picardi, A, Invernizzi, P, Vespasiani-Gentilucci, U, Carbone, M, Feletti, V, Mussetto, A, Venere, R, Bernaccioni, G, Graciella Pigozzi, M, Fagiuoli, S, Terreni, N, Pozzoni, P, Baiocchi, L, Grassi, G, Vinci, M, Bellia, V, Boldizzoni, R, Casella, S, Omazzi, B, Poggi, G

Background & Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9816bc22cfb3ec589218e0c92665608
https://hdl.handle.net/11391/1545316

Health-economic evaluation of different organizational models to manage the Hepatitis C patient journey

Autor: Fagiuoli, S., Pasulo, L., Maggiolo, F., Spinella, R., Del Poggio, P., Boldizzoni, R., Di Marco, M., Aronica, A., Benedetti, C., Correale, P., Garavaglia, C., Nicora, C.

Publikováno v: In Digestive and Liver Disease February 2018 50(1) Supplement:31-31

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Treatment of patients with chronic hepatitis C infection in Lombardia: A report by the Lombardia Hepatitis Network

Autor: Aghemo, A., Raffaele Bruno, Colombo, M., Medaglia, M., Puoti, M., Rizzardini, G., Fagiuoli, S., Cologni, G., Di Marco, M., Maggiolo, F., Pasulo, L., Colpani, M., Perini, M., Colloredo, G., Lazzaroni, S., Colombo, S., Boldizzoni, R., Del Poggio, P., Magni, C., D Ambrosio, R., Zuin, M., Rumi, M. G., Soncini, M., Valenti, L., Bhoori, S., Monforte, A. D., Quirino, T., Filice, G., Gubertini, G., Colli, A., Pan, A., Giglio, O., Pusterla, L., Santoro, D., Merlini, R., Borzio, M., Buscarini, E.

Publikováno v: Scopus-Elsevier
Web of Science

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1943472256146351f1ad6dead2254fda
http://www.scopus.com/inward/record.url?eid=2-s2.0-85016318993&partnerID=MN8TOARS

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

Autor: Sergio Lazzaroni, Paolo Grossi, Chiara Molteni, Maria Grazia Valsecchi, Pietro Lampertico, Luca Valenti, Alessio Aghemo, Alessia Giorgini, Antonella d'Arminio Monforte, Roberta D'Ambrosio, Federico Gatti, Omar Giglio, Daniele Bella, Davide Paolo Bernasconi, Giuseppe Lapadula, Sherrie Bhoori, Hamid Hasson, Monica Schiavini, Elisa Colella, Roberto Boldizzoni, A. Ciaccio, Simona Landonio, Andrea Capretti, Maria Cristina Vinci, Giuliano Rizzardini, Barbara Menzaghi, Elisabetta Degasperi, Caterina Uberti-Foppa, Chiara Baiguera, Andrea Lombardi, Gianpiero Aimo, Layla Pagnucco, Paolo Perini, Giuliana Cologni, Natalia Terreni, Paolo Bonfanti, Mauro Viganò, Paolo Viganò, Alessandro Soria, Roberto Rossotti, Massimo Puoti, Ombretta Spinelli, Canio Carriero, Silvia Polo, Guglielmo Marco Migliorino, Silvia Colombo, Riccardo Centenaro, Luisa Pasulo, Anna De Bona, E. Dionigi, Paolo Poggio, Franco Noventa, Isabella Carderi, Angelo Pan, Angiola Spinetti, Mariella Di Marco, Cecilia Liani, Stefano Fagiuoli, Marie Graciella Pigozzi, Marco Fava, Massimo Graffeo, Maria Grazia Rumi, Alberto Colombo

Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e24f9590f3eeea82bd0c70867a0c4cc9